Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging AI and machine learning for oncology drug discovery, has announced it will report its Q2 2024 financial results on Wednesday, August 14, 2024, before market open. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET on the same day.
Investors can access the call via toll-free (877-407-3982) or international (201-493-6780) numbers, using Conference ID 13748154. A live webcast will also be available on the company's investor relations website.
Predictive Oncology Inc. (NASDAQ: POAI), un'azienda orientata alla scienza che sfrutta l'IA e il machine learning per la scoperta di farmaci in oncologia, ha annunciato che riferirà i suoi risultati finanziari del Q2 2024 mercoledì 14 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà una call di aggiornamento aziendale e una diretta audio via web alle 8:30 a.m. ET nello stesso giorno.
Gli investitori possono accedere alla chiamata tramite il numero verde (877-407-3982) o il numero internazionale (201-493-6780), utilizzando l'ID Conferenza 13748154. Sarà inoltre disponibile una diretta web sul sito delle relazioni con gli investitori dell'azienda.
Predictive Oncology Inc. (NASDAQ: POAI), una empresa impulsada por la ciencia que utiliza IA y aprendizaje automático para el descubrimiento de fármacos oncológicos, ha anunciado que informará sobre sus resultados financieros del Q2 2024 el miércoles 14 de agosto de 2024, antes de la apertura del mercado. La compañía llevará a cabo una conferencia telefónica de actualización corporativa y una transmisión de audio en vivo a las 8:30 a.m. ET el mismo día.
Los inversores pueden acceder a la llamada a través del número gratuito (877-407-3982) o del número internacional (201-493-6780), utilizando el ID de Conferencia 13748154. También estará disponible una transmisión en vivo en el sitio web de relaciones con inversores de la empresa.
Predictive Oncology Inc. (NASDAQ: POAI)는 AI 및 머신 러닝을 활용하여 종양학 약물 발견을 진행하는 과학 중심 기업으로, 2024년 2분기 재무 결과를 2024년 8월 14일 수요일 시장 개장 전에 발표한다고 발표했습니다. 회사는 같은 날 미국 동부 표준시 기준 오전 8시 30분에 기업 업데이트 전화 회의 및 라이브 오디오 웹캐스트를 개최합니다.
투자자는 무료 전화번호 (877-407-3982) 또는 국제 전화번호 (201-493-6780)를 통해 전화를 받을 수 있으며, 회의 ID 13748154를 사용해야 합니다. 회사의 투자자 관계 웹사이트에서도 라이브 웹캐스트가 제공됩니다.
Predictive Oncology Inc. (NASDAQ: POAI), une entreprise axée sur la science qui utilise l'IA et l'apprentissage automatique pour la découverte de médicaments en oncologie, a annoncé qu'elle publiera ses résultats financiers du T2 2024 le mercredi 14 août 2024, avant l'ouverture des marchés. L'entreprise organisera un appel de mise à jour d'entreprise et un webinaire audio en direct à 8h30, heure de l'Est le même jour.
Les investisseurs peuvent accéder à l'appel via le numéro sans frais (877-407-3982) ou le numéro international (201-493-6780), en utilisant l'ID de conférence 13748154. Un webinaire en direct sera également disponible sur le site internet des relations investisseurs de l'entreprise.
Predictive Oncology Inc. (NASDAQ: POAI), ein wissenschaftlich orientiertes Unternehmen, das KI und maschinelles Lernen für die Entdeckung von Onkologika nutzt, hat angekündigt, dass es am Mittwoch, den 14. August 2024, vor der Markteröffnung seine finanziellen Ergebnisse für das 2. Quartal 2024 berichten wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz zur Unternehmensaktualisierung und eine Live-Audio-Webcast anbieten.
Investoren können die Konferenz über die gebührenfreie Nummer (877-407-3982) oder die internationale Nummer (201-493-6780) erreichen, indem sie die Konferenz-ID 13748154 verwenden. Ein Live-Webcast wird auch auf der Investor-Relations-Website des Unternehmens zur Verfügung stehen.
- None.
- None.
Management to host conference call and webcast at 8:30am ET
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.
| Live Conference Call & Webcast: | |
| Toll Free: | 877-407-3982 |
| International: | 201-493-6780 |
| Conference ID: | 13748154 |
| Call me™: | here |
A live webcast will be available here or in the Investors section of the Predictive Oncology website at https://investors.predictive-oncology.com/events-and-presentations.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with
Contact:
Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
FAQ
When will Predictive Oncology (POAI) report its Q2 2024 financial results?
What time is Predictive Oncology's (POAI) Q2 2024 earnings conference call?
How can investors access Predictive Oncology's (POAI) Q2 2024 earnings call?
